Cross-linked Volume-stable Collagen Matrix Versus Connective Tissue Graft at Implant Site.

U

University of Florence (UNIFI)

Status

Active, not recruiting

Conditions

Soft Tissue Augmentation at Dental Implants
Edentulous Alveolar Ridge Atrophy

Treatments

Device: VCMX
Procedure: CTG

Study type

Interventional

Funder types

Other

Identifiers

NCT05458271
VCMX vs CTG

Details and patient eligibility

About

Recent data suggested that an adequate volume of Keratinized Tissue (KT) around dental implant is a key factor to obtain aesthetic outcomes and to support easy long-term maintenance. The aim of this RCT is to test the volume-stable collagen matrix (VCMX) vs the Connective Tissue Graft (CTG) for peri-implant soft tissue augmentation during implant uncovering.

Enrollment

100 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ≥18 years.
  • No systemic diseases or pregnancy.
  • Self-reported smoking ≤10 cigarettes/day.
  • No probing depths ≥5 mm
  • Full-mouth plaque score (FMPS) and full-mouth bleeding score (FMBS) ≤15% (measured at four sites per tooth).
  • Single dental implant with a scheduled for soft tissue augmentation procedure at the time of uncovering.
  • Need of soft tissue augmentation for aesthetic purpose and/or functional reasons
  • No previous soft tissue augmentation procedure at experimental site.

Exclusion criteria

  • General contraindications for dental and/or surgical treatments
  • Concurrent or previous immunosuppressant, bisphosphonate or high dose corticosteroid therapy
  • Inflammatory and autoimmune disease of oral cavity
  • History of myeloma, respiratory tract cancer, breast cancer, prostate cancer or kidney cancer requiring chemotherapy or radiotherapy within the past five years
  • Radiotherapy of head area
  • Disease or condition affecting connective tissue metabolism (e.g. disease of arteries in the operating zone, bone metabolic diseases, alcohol abuse, treatment with anticoagulants)
  • Any systemic diseases that affect bone metabolism (e.g thyroid dysfunction, autoimmune disease)
  • Untreated acute periodontal disease
  • Patients who smoke more than 10 cigarettes/day will be excluded from the study
  • Diabetes
  • Allergy to the collagen
  • Pregnant or lactating women
  • Women of child bearing age, not using a highly effective method of birth control
  • Participation in an investigational device, drug or biologic study within the last 24 weeks prior to the study start

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

100 participants in 2 patient groups

VCMX
Experimental group
Description:
All patients will be treated by scaling/root planing to obtain infection control if needed. In addition, patients will receive oral hygiene instructions. The test group will be treated with add of VCMX. Following the local anesthesia, a split thickness flap will be raised-up to uncover the implant screw. Care will be taken to preserve pre-existing KT amount. A mesio-distal and apical partial thickness dissection will be performed to release residual muscle tension and allow the passive apical displacement of the flap. The randomisation envelope will be then opened. In test group the VCMX will be gently shaped and secured under the flap with suture. Care will be applied to completely cover the xenograft.
Treatment:
Device: VCMX
CTG
Active Comparator group
Description:
The control group patients will be treated by flap surgery with add of CTG. In the control group (APF) a CTG harvested from palate will be secured under the flap with suture.
Treatment:
Procedure: CTG

Trial contacts and locations

1

Loading...

Central trial contact

Luigi Barbato, Dr.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems